Clinical Benefit From Immune Checkpoint Blockade in Sclerosing Epithelioid Fibrosarcoma: A Translocation-Associated Sarcoma

JCO Precis Oncol. 2021 Nov:5:1-5. doi: 10.1200/PO.20.00201.

Authors

Sahil D Doshi¹, Jay Oza², Helen Remotti³, Fabrizio Remotti³, Matthew P Moy⁴, Gary K Schwartz², Matthew Ingham²

Affiliations

¹ Department of Medicine, Columbia University Irving Medical Center, New York, NY.
² Division of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY.
³ Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY.
⁴ Department of Radiology, Columbia University Irving Medical Center, New York, NY.

PMID: 34994591
DOI: 10.1200/PO.20.00201

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Aged
B7-H1 Antigen / metabolism
CD8 Antigens / metabolism
Female
Fibrosarcoma / diagnostic imaging
Fibrosarcoma / drug therapy*
Fibrosarcoma / pathology
Humans
Immune Checkpoint Inhibitors / therapeutic use*
Magnetic Resonance Imaging
Male
Mucin-4 / metabolism
Myxosarcoma / diagnostic imaging
Myxosarcoma / drug therapy*
Myxosarcoma / pathology
Positron-Emission Tomography
Tomography, X-Ray Computed

Substances

B7-H1 Antigen
CD274 protein, human
CD8 Antigens
Immune Checkpoint Inhibitors
MUC4 protein, human
Mucin-4